1921
Volume 76, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

A combination of atovaquone-proguanil (Malarone; GlaxoSmithKline, Research Triangle Park, NC) was previously shown to be highly effective in the treatment of uncomplicated malaria. However, there are only limited recent efficacy data, particularly from regions of multidrug resistance. In this study, we examined the efficacy of atovaquone-proguanil for the treatment of uncomplicated malaria on the Thailand-Myanmar border. Patients were given directly observed atovaquone-proguanil (1,000 mg/400 mg) once a day for three days and followed-up for four weeks in a non-transmission area. Of 140 eligible patients enrolled in this open-label study, 97.8% (95% confidence interval = 95.4–100%) responded to therapy and remained clear of parasitemia at follow-up. Mean parasite clearance time was 41.9 hours and mean fever clearance time was 37.1 hours. On the basis of genotyping, three cases of treatment failure were identified (1 RIII and 2 RI). These data indicate that atovaquone-proguanil remains highly efficacious for the treatment of multidrug-resistant malaria in Thailand.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.76.655
2007-04-01
2017-11-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/76/4/0760655.html?itemId=/content/journals/10.4269/ajtmh.2007.76.655&mimeType=html&fmt=ahah

References

  1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2 : 209–218.
  2. Borrmann S, Faucher JF, Bagaphou T, Missinou MA, Binder RK, Pabisch S, Rezbach P, Matsiegui PB, Lell B, Miller G, Kremsner PG, 2003. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Clin Infect Dis 37 : 1441–1447.
  3. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ, Hutchinson DB, 1999. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 60 : 526–532.
  4. Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB, 1999. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 179 : 1587–1590.
  5. Fry M, Pudney M, 1992. Site of action of the antimalarial hydrox-ynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43 : 1545–1553.
  6. Srivastava IK, Rottenberg H, Vaidya AB, 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 272 : 3961–3966.
  7. Reynolds MG, Roos DS, 1998. A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum. J Biol Chem 273 : 3461–3469.
  8. Gay F, Bustos D, Traore B, Jardinel C, Southammavong M, Ciceron L, Danis MM, 1997. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am J Trop Med Hyg 56 : 315–317.
  9. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB, 1999. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 33 : 704–711.
  10. Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegardh N, Berezcky S, Bjorkman A, 2003. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 326 : 628–629.
  11. Schwartz E, Bujanover S, Kain KC, 2003. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 37 : 450–451.
  12. Schwobel B, Alifrangis M, Salanti A, Jelinek T, 2003. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2 : 5.
  13. Kuhn S, Gill MJ, Kain KC, 2005. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveler to west Africa. Am J Trop Med Hyg 72 : 407–409.
  14. David KP, Alifrangis M, Salanti A, Vestergaard LS, Ronn A, Bygbjerg IB, 2003. Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis 35 : 897–898.
  15. Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J, 2006. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 57 : 110–115.
  16. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G, 2002. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 1 : 1.
  17. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G, Richter J, 2004. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis 190 : 1541–1546.
  18. Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T, 2004. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J 3 : 14.
  19. Chemotherapy of malaria and resistance to antimalarials, 1973. Report of a WHO scientific group. World Health Organ Tech Rep Ser 529 : 1–121.
  20. Labbe AC, Patel S, Crandall I, Kain KC, 2003. A molecular surveillance system for global patterns of drug resistance in imported malaria. Emerg Infect Dis 9 : 33–36.
  21. Ohrt C, Mirabelli-Primdahl L, Looareesuwan S, Wilairatana P, Walsh D, Kain KC, 1999. Determination of failure of treatment of Plasmodium falciparum infection by using polymerase chain reaction single-strand conformational polymorphism fingerprinting. Clin Infect Dis 28 : 847–852.
  22. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG, 1996. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 347 : 1511–1514.
  23. de Alencar FE, Cerutti C Jr, Durlacher RR, Boulos M, Alves FP, Milhous W, Pang LW, 1997. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 175 : 1544–1547.
  24. Anabwani G, Canfield CJ, Hutchinson DB, 1999. Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J 18 : 456–461.
  25. Mulenga M, Sukwa TY, Canfield CJ, Hutchinson DB, 1999. Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther 21 : 841–852.
  26. van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, Brockman A, Villegas L, Looareesuwan S, White NJ, Nosten F, 2002. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 35 : 1498–1504.
  27. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q, 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44 : 2100–2108.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.76.655
Loading
/content/journals/10.4269/ajtmh.2007.76.655
Loading

Data & Media loading...

  • Received : 11 Oct 2006
  • Accepted : 01 Jan 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error